Cladribine (oral)

🧮 Dose calculator

Multiple sclerosis (relapsing) · Regimen source: FDA Mavenclad · 2.2FDA Mavenclad · 2.5FDA Mavenclad · 2.6FDA Mavenclad · 2.4

👥 Special populations

• 🤰 PregnancyContraindicated

  Label: contraindicated in pregnancy. FDA Mavenclad · 4

  “MAVENCLAD is contraindicated: in patients with current malignancy [see Warnings and Precautions (5.1) ]. in pregnant women and in females and males of reproductive potential who do not plan to use effective contraception during MAVENCLAD dosing and for 6 months after the last dose in each treatment course for females, …”

• 🤱 BreastfeedingContraindicated

  Label: contraindicated while breastfeeding. FDA Mavenclad · 4

  “… atients with a history of hypersensitivity to cladribine [see Warnings and Precautions (5.8) ]. in females intending to breastfeed on a MAVENCLAD treatment day and for 10 days after the last dose [see Use in Specific Populations (8.2) ].”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Mavenclad · 8.4

  “The safety and effectiveness in pediatric patients (below 18 years of age) have not been established.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Mavenclad · 8.5

  “Caution is recommended when MAVENCLAD is used in elderly patients, taking into account the potential greater frequency of decreased hepatic, renal, or cardiac function, concomitant diseases, and other drug therapy.”

• ⚥ Females & males of reproductive potentialUse with caution

  Label has advice on pregnancy testing, contraception or fertility for females and males. FDA Mavenclad · 8.3

  “Contraception Females Females of reproductive potential should prevent pregnancy by use of effective contraception during MAVENCLAD dosing and for at least 6 months after the last dose in each treatment course.”